Sara G Llames

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/218092/publications.pdf Version: 2024-02-01



SADA CLIAMES

#	Article	IF	CITATIONS
1	Natural Occurrence of Autoantibodies against Basement Membrane Proteins in Epidermolysis Bullosa. Journal of Investigative Dermatology, 2022, 142, 2014-2019.e3.	0.7	4
2	Polymerizable Skin Hydrogel for Full Thickness Wound Healing. International Journal of Molecular Sciences, 2022, 23, 4837.	4.1	8
3	Xeno-free approach for the expansion of human adipose derived mesenchymal stem cells for ocular therapies. Experimental Eye Research, 2021, 202, 108358.	2.6	0
4	Transcriptomic Analysis of a Diabetic Skin-Humanized Mouse Model Dissects Molecular Pathways Underlying the Delayed Wound Healing Response. Genes, 2021, 12, 47.	2.4	6
5	Efficient CRISPR-Cas9-Mediated Gene Ablation in Human Keratinocytes to Recapitulate Genodermatoses: Modeling of Netherton Syndrome. Molecular Therapy - Methods and Clinical Development, 2020, 18, 280-290.	4.1	10
6	Development of an in-house reconstructed human epidermis model as an alternative method in skin corrosion assessment. Toxicology in Vitro, 2020, 65, 104779.	2.4	4
7	Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancerâ€prone genodermatoses. British Journal of Dermatology, 2019, 181, 512-522.	1.5	46
8	Human plasma gels: Their preparation and rheological characterization for cell culture applications in tissue engineering. Journal of the Mechanical Behavior of Biomedical Materials, 2019, 89, 107-113.	3.1	2
9	Deletion of a Pathogenic Mutation-Containing Exon of COL7A1 Allows Clonal Gene Editing Correction of RDEB Patient Epidermal Stem Cells. Molecular Therapy - Nucleic Acids, 2018, 11, 68-78.	5.1	35
10	ldentification of two rare and novel large deletions in <i><scp>ITGB</scp>4</i> gene causing epidermolysis bullosa with pyloric atresia. Experimental Dermatology, 2016, 25, 269-274.	2.9	11
11	Ectopic bone formation during tissue-engineered cartilage repair using autologous chondrocytes and novel plasma-derived albumin scaffolds. Journal of Cranio-Maxillo-Facial Surgery, 2016, 44, 1743-1749.	1.7	13
12	Feeder Layer Cell Actions and Applications. Tissue Engineering - Part B: Reviews, 2015, 21, 345-353.	4.8	122
13	Tissue-Engineered Oral Mucosa Grafts for Intraoral Lining Reconstruction of the Maxilla and Mandible With a Fibula Flap. Journal of Oral and Maxillofacial Surgery, 2015, 73, 195.e1-195.e16.	1.2	23
14	Long-Term Survival of Type XVII Collagen Revertant Cells in an Animal Model of Revertant Cell Therapy. Journal of Investigative Dermatology, 2014, 134, 571-574.	0.7	23
15	Tissue-Engineered Oral Mucosa for Mucosal Reconstruction in a Pediatric Patient with Hemifacial Microsomia and Ankyloglossia. Cleft Palate-Craniofacial Journal, 2014, 51, 246-251.	0.9	15
16	The regenerative potential of fibroblasts in a new diabetesâ€induced delayed humanised wound healing model. Experimental Dermatology, 2013, 22, 195-201.	2.9	34
17	Keratinocyte cell lines derived from severe generalized recessive <scp>E</scp> pidermolysis <scp>B</scp> ullosa patients carrying a highly recurrent <i><scp>COL</scp>7A1</i> homozygous mutation: models to assess cell and gene therapies <i>in vitro</i> and <i>in vivo</i> . Experimental Dermatology, 2013, 22, 601-603.	2.9	20
18	Potentiation of acute morphineâ€induced analgesia measured by a thermal test in bone cancerâ€bearing mice. Fundamental and Clinical Pharmacology, 2012, 26, 363-372.	1.9	10

SARA G LLAMES

#	Article	IF	CITATIONS
19	Tissue Bioengineering and Artificial Organs. Advances in Experimental Medicine and Biology, 2012, 741, 314-336.	1.6	8
20	Clinical outcomes after the use of complete autologous oral mucosa equivalents: preliminary cases. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012, 113, e4-e11.	0.4	10
21	Use of an autologous bioengineered composite skin in extensive burns: Clinical and functional outcomes. A multicentric study. Burns, 2011, 37, 580-589.	1.9	37
22	Two novel recessive mutations in KRT14 identified in a cohort of 21 Spanish families with epidermolysis bullosa simplex. British Journal of Dermatology, 2011, 165, 683-692.	1.5	24
23	Spinal and peripheral analgesic effects of the CB ₂ cannabinoid receptor agonist AM1241 in two models of bone cancerâ€induced pain. British Journal of Pharmacology, 2010, 160, 561-573.	5.4	75
24	The first <i>COL7A1</i> mutation survey in a large Spanish dystrophic epidermolysis bullosa cohort: c.6527insC disclosed as an unusually recurrent mutation. British Journal of Dermatology, 2010, 163, 155-161.	1.5	53
25	In Vivo Assessment of Acute UVB Responses in Normal and Xeroderma Pigmentosum (XP-C) Skin-Humanized Mouse Models. American Journal of Pathology, 2010, 177, 865-872.	3.8	30
26	Room Temperature Storage of Cultured Human Articular Chondrocytes. Cell Preservation Technology, 2008, 6, 199-206.	0.6	1
27	Cancellous bone homograft storage with aluminium-polyethylene bags. Cell and Tissue Banking, 2006, 7, 203-206.	1.1	1
28	Clinical Results of an Autologous Engineered Skin. Cell and Tissue Banking, 2006, 7, 47-53.	1.1	93
29	Implantation of Tumoral XC Cells Induces Chronic, Endothelin-Dependent, Thermal Hyperalgesia in Mice. Cellular and Molecular Neurobiology, 2004, 24, 269-281.	3.3	19
30	Human plasma as a dermal scaffold for the generation of a completely autologous bioengineered skin. Transplantation, 2004, 77, 350-355.	1.0	168
31	Initial thermal heat hypoalgesia and delayed hyperalgesia in a murine model of bone cancer pain. Brain Research, 2003, 969, 102-109.	2.2	65
32	IL-1α (â^ 889) promoter polymorphism is a risk factor for osteomyelitis. , 2003, 119A, 132-136.		35
33	Tratamientos futuros de las úlceras cutáneas crónicas. Angiologia, 2003, 55, 288-290.	0.0	Ο